Vanderbilt University Medical Center, Nashville, Tennessee.
Boston Children's Hospital, Boston, Massachusetts.
Clin Gastroenterol Hepatol. 2020 Mar;18(3):612-619.e1. doi: 10.1016/j.cgh.2019.04.037. Epub 2019 Apr 19.
BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is commonly used to treat Clostridium difficile infection (CDI). CDI is an increasing cause of diarrheal illness in pediatric patients, but the effects of FMT have not been well studied in children. We performed a multi-center retrospective cohort study of pediatric and young adult patients to evaluate the efficacy, safety, and factors associated with a successful FMT for the treatment of CDI.
We performed a retrospective study of 372 patients, 11 months to 23 years old, who underwent FMT at 18 pediatric centers, from February 1, 2004, to February 28, 2017; 2-month outcome data were available from 335 patients. Successful FMT was defined as no recurrence of CDI in the 2 months following FMT. We performed stepwise logistic regression to identify factors associated with successful FMT.
Of 335 patients who underwent FMT and were followed for 2 months or more, 271 (81%) had a successful outcome following a single FMT and 86.6% had a successful outcome following a first or repeated FMT. Patients who received FMT with fresh donor stool (odds ratio [OR], 2.66; 95% CI, 1.39-5.08), underwent FMT via colonoscopy (OR, 2.41; 95% CI, 1.26-4.61), did not have a feeding tube (OR, 2.08; 95% CI, 1.05-4.11), or had 1 less episode of CDI before FMT (OR, 1.20; 95% CI, 1.04-1.39) had increased odds for successful FMT. Seventeen patients (4.7%) had a severe adverse event during the 3-month follow-up period, including 10 hospitalizations.
Based on the findings from a large multi-center retrospective cohort, FMT is effective and safe for the treatment of CDI in children and young adults. Further studies are required to optimize the timing and method of FMT for pediatric patients-factors associated with success differ from those of adult patients.
粪便微生物群移植(FMT)常用于治疗艰难梭菌感染(CDI)。CDI 是儿童腹泻病日益增多的病因,但 FMT 对儿童的疗效尚未得到很好的研究。我们进行了一项多中心回顾性队列研究,以评估粪便微生物群移植治疗 CDI 的疗效、安全性和与成功治疗相关的因素。
我们对 2004 年 2 月 1 日至 2017 年 2 月 28 日在 18 家儿科中心接受 FMT 的 372 名 11 个月至 23 岁的儿科和年轻成人患者进行了回顾性研究;335 名患者可获得 2 个月的随访结果。成功的 FMT 定义为 FMT 后 2 个月内 CDI 无复发。我们进行逐步逻辑回归以确定与成功 FMT 相关的因素。
在 335 名接受 FMT 并随访 2 个月或更长时间的患者中,271 名(81%)在单次 FMT 后获得成功结局,86.6%在首次或重复 FMT 后获得成功结局。接受新鲜供体粪便 FMT(比值比 [OR],2.66;95%置信区间 [CI],1.39-5.08)、接受结肠镜 FMT(OR,2.41;95%CI,1.26-4.61)、无喂养管(OR,2.08;95%CI,1.05-4.11)或在 FMT 前 CDI 发作次数少 1 次(OR,1.20;95%CI,1.04-1.39)的患者,其 FMT 成功的可能性更高。在 3 个月的随访期间,17 名患者(4.7%)发生 17 例严重不良事件,包括 10 例住院。
基于一项大型多中心回顾性队列研究的结果,FMT 对儿童和年轻成人 CDI 的治疗是有效且安全的。需要进一步研究来优化儿科患者的 FMT 时机和方法-与成人患者相关的成功因素不同。